B. Riley Boosts Earnings Estimates for Tango Therapeutics

Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) - Analysts at B. Riley upped their FY2025 earnings per share estimates for Tango Therapeutics in a report released on Monday, June 9th. B. Riley analyst Y. Zhi now expects that the company will earn ($1.37) per share for the year, up from their prior forecast of ($1.49). The consensus estimate for Tango Therapeutics' current full-year earnings is ($1.19) per share. B. Riley also issued estimates for Tango Therapeutics' FY2026 earnings at ($1.03) EPS.

Separately, HC Wainwright reissued a "buy" rating and set a $13.00 price objective on shares of Tango Therapeutics in a research report on Monday, April 14th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $12.20.

Tango Therapeutics Stock Down 7.1%

TNGX traded down $0.36 during trading on Thursday, reaching $4.69. 2,443,774 shares of the stock traded hands, compared to its average volume of 1,476,064. The stock has a market capitalization of $508.37 million, a PE ratio of -3.97 and a beta of 1.24. The stock's 50-day moving average is $2.02 and its 200 day moving average is $2.40. Tango Therapeutics has a 12 month low of $1.03 and a 12 month high of $12.02.

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported ($0.36) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.02). The firm had revenue of $5.39 million for the quarter, compared to the consensus estimate of $6.73 million. Tango Therapeutics had a negative net margin of 284.42% and a negative return on equity of 49.64%.

Hedge Funds Weigh In On Tango Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Teacher Retirement System of Texas lifted its position in Tango Therapeutics by 35.8% in the 4th quarter. Teacher Retirement System of Texas now owns 14,544 shares of the company's stock valued at $45,000 after acquiring an additional 3,831 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in Tango Therapeutics by 29.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 20,998 shares of the company's stock valued at $65,000 after acquiring an additional 4,813 shares in the last quarter. Deutsche Bank AG lifted its position in Tango Therapeutics by 24.1% in the 4th quarter. Deutsche Bank AG now owns 36,653 shares of the company's stock valued at $113,000 after acquiring an additional 7,128 shares in the last quarter. Wells Fargo & Company MN lifted its position in Tango Therapeutics by 51.7% in the 4th quarter. Wells Fargo & Company MN now owns 22,292 shares of the company's stock valued at $69,000 after acquiring an additional 7,599 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its position in Tango Therapeutics by 9.9% in the 1st quarter. Bank of New York Mellon Corp now owns 113,233 shares of the company's stock valued at $155,000 after acquiring an additional 10,213 shares in the last quarter. Institutional investors own 78.99% of the company's stock.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.